Loading...
Please wait, while we are loading the content...
c-Met as a Prognostic Marker in Gastric Cancer: A Systematic Review and Meta-Analysis
| Content Provider | Semantic Scholar |
|---|---|
| Author | Yu, Shan Yu, Yiyi Zhao, Naiqing Cui, Jianlan Liu, Tianshu |
| Copyright Year | 2013 |
| Abstract | BACKGROUND c-Met has been recognized as an important therapeutic target in gastric cancer, but the prognostic property of the c-Met status is still unclear. We aimed to characterize the prognostic effect of c-Met by systematic review and meta-analysis. METHODS We identified 15 studies assessing survival in gastric cancer by c-Met status. Effect measure of interest was hazard ratio (HR) for survival. Meta-regression was performed to estimate the relationship between HR and disease stage. Random-effects meta-analyses were used to account for heterogeneity. RESULTS 15 eligible studies provided outcome data stratified by c-Met status in 2210 patients. Meta-analysis of the HRs indicated a significantly poorer Os in patients with high c-Met expression (average HR=2.112, 95%CI: 1.622-2.748). Subgroup analysis showed the prognostic effect of c-Met was identical in protein-level and gene-level based methodology. The same effect was also seen in Asian and Western ethnicity subgroup analysis. Meta-regression showed HR was not associated with disease stage. CONCLUSIONS Patients with tumors that harbor high c-Met expression are more likely to have a worse Os, with this prognostic effect independent of disease stage. c-Met status should be evaluated in clinical prognosis. |
| File Format | PDF HTM / HTML |
| DOI | 10.1371/journal.pone.0079137 |
| PubMed reference number | 24223894 |
| Journal | Medline |
| Volume Number | 8 |
| Alternate Webpage(s) | http://ftp.ncbi.nlm.nih.gov/pub/pmc/d6/aa/pone.0079137.PMC3817069.pdf |
| Journal | PloS one |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
